Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia

Oncology Letters

Volumn 10, Issue 3, 2015, Pages 1259-1266

  Dou, Xiaotan ^a   Xiao, Junhua ^b   Jin, Ziliang ^c   Zheng, Ping ^b  

^a NANJING UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

5 aminosalicylic acid; Colonic neoplasms; Peroxisome proliferator activated receptor ; Ulcerative colitis

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOWN REGULATION; DYSPLASIA; EXPERIMENTAL COLITIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY BOWEL DISEASE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; ULCERATIVE COLITIS;

EID: 84937393858     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3397     Document Type: Article

References (35)

1. Munkholm P: Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2): 1-5, 2003.
2. Cheng Y and Desreumaux P: 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J Gastroenterol11: 309-314, 2005.
3. Debril MB, Renaud JP, Fajas L and Auwerx J: The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med Berl 79: 30-47, 2001.
4. Hontecillas R and Bassaganya-Riera J: Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ Tcell-mediated protection against colitis. J Immunol 178: 2940-2949, 2007.
5. Schwab M, Reynders V, Loitsch S, Shastri YM, SteinhilberD, Schröder O and Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29: 1407-1414, 2008.
6. van Staa TP, Card T, Logan RF and Leufkens HG: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: A large epidemiological study. Gut 54: 1573-1578, 2005.
7. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, etal: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201: 1205-1215, 2005.
8. Koelink PJ, Mieremet-Ooms MA, Corver WE, Wolanin K, Hommes DW, Lamers CB and Verspaget HW: 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes. Inflamm Bowel Dis 16: 379-389, 2010.
9. Kohno H, Suzuki R, Sugie S and Tanaka T: Suppression of colitis-related mouse colon carcinogenesis by a COX-2inhibitor and PPAR ligands. BMC Cancer 5: 46, 2005.
10. Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
11. Ni J, Chen SF and Hollander D: Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 39: 234-241, 1996.
12. Cooper HS, Everley L, Chang WC, Pfeiffer G, Lee B, Murthy S and Clapper ML: The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121: 1407-1416, 2001.
13. Tanaka T, Kohno H, Suzuki R, Hata K, Sugie S, Niho N, SakanoK, Takahashi M and Wakabayashi K: Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: Inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer 118: 25-34, 2006.
14. Murano M, Maemura K, Hirata I, Toshina K, Nishikawa T, Hamamoto N, Sasaki S, Saitoh O and Katsu K: Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 120: 51-58, 2000.
15. Onderdonk AB and Bartlett JG: Bacteriological studies of experimental ulcerative colitis. Am J Clin Nutr 32: 258-265, 1979.
16. JinZ, JiangW, JiaoF, HuH, GuoZ, WangL and WangL: Decreased expression of histone deacetylase10 predicts poor prognosis of gastric cancer patients, Int J Clin Exp Pathol7: 5872-5879, 2014.
17. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J and Desreumaux P: Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360: 1410-1418, 2002.
18. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, RomanoO, Chavatte P, Chamaillard M and Desreumaux P: PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55: 1341-1349, 2006.
19. Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5: 419-429, 2004.
20. Chen CW, Chang YH, Tsi CJ and Lin WW: Inhibition of IFN-gamma-mediated inducible nitric oxide synthase induction by the peroxisome proliferator-activated receptor gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, involves inhibition of the upstream Janus kinase/STAT1signaling pathway. JImmunol171: 979-988, 2003.
21. Sánchez-Hidalgo M, Martín AR, Villegas I and Alarcón De La Lastra C: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69: 1733-1744, 2005.
22. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L and Farrar WL: Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275: 4541-4544, 2000.
23. Krishnan A, Nair SA and Pillai MR: Biology of PPAR gamma in cancer: A critical review on existing lacunae. Curr Mol Med7: 532-540, 2007.
24. Hontecillas R, Horne WT, Climent M, Guri AJ, Evans C, ZhangY, Sobral BW and Bassaganya-Riera J: Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol4: 304-313, 2011.
25. Yamamoto-Furusho JK, Peñaloza-Coronel A, Sánchez-MuñozF, Barreto-Zuñiga R and Dominguez-Lopez A: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis 17: 680-681, 2011.
26. Farrell RJ and Peppercorn MA: Ulcerative colitis. Lancet 359: 331-340, 2002.
27. Ikeda I, Tomimoto A, Wada K, Fujisawa T, Fujita K, YonemitsuK, Nozaki Y, Endo H, Takahashi H, Yoneda M, etal: 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Clin Cancer Res 13: 6527-6531, 2007.
28. Koelink PJ, Robanus-Maandag EC, Devilee P, Hommes DW, Lamers CB and Verspaget HW: 5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model. Carcinogenesis 30: 1217-1224, 2009.
29. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, FenoglioCM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, etal: Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 14: 931-968, 1983.
30. Clapper ML, Gary MA, Coudry RA, Litwin S, Chang WC, Devarajan K, Lubet RA and Cooper HS: 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 14: 1341-1347, 2008.
31. Saif MW and Chu E: Biology of colorectal cancer. Cancer J 16: 196-201, 2010.
32. Liu J and Farmer SR: Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279: 45020-45027, 2004.
33. Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO and Tozun N: Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease. J Gastrointestin Liver Dis 17: 433-437, 2008.
34. Shrestha UK, Karimi O, Crusius JB, Zhou F, Wang Z, Chen Z, van Bodegraven AA, Xiao J, Morré SA, WangH, etal: Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. Inflamm Bowel Dis 16: 312-319, 2010.
35. Jennewein C, von Knethen A, Schmid T and BrüneB: MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization. JBiol Chem285: 11846-11853, 2010.